

Shijie Ren

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8889347/shijie-ren-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

451
citations

12
h-index

20
g-index

28
ext. papers

563
ext. citations

3.9
avg, IF

3.37
L-index

#	Paper	IF	Citations
27	R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study. <i>Pharmacoeconomics</i> , 2020 , 38, 765-776	4.4	3
26	Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. <i>Health Technology Assessment</i> , 2020 , 24, 1-490	4.4	11
25	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. <i>Pharmacoeconomics</i> , 2020 , 38, 193-204	4.4	9
24	Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019 , 37, 1073-1080	4.4	3
23	Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2019 , 35, 36-44	1.8	4
22	Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018 , 36, 769-778	4.4	5
21	Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. <i>Medical Decision Making</i> , 2018 , 38, 531-542	2.5	12
20	A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. <i>Pharmacoeconomics</i> , 2018 , 36, 341-347	4.4	3
19	Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018 , 36, 1063-1072	4.4	4
18	Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018 , 36, 1427-1437	4.4	3
17	Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2017 , 3, 119-129	5.1	21
16	Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. <i>Medical Decision Making</i> , 2017 , 37, 377-390	2.5	51
15	Complementary and Alternative Medicine for Management of Premature Ejaculation: A Systematic Review. <i>Sexual Medicine</i> , 2017 , 5, e1-e18	2.7	2
14	How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2017 , 35, 767-776	4.4	10
13	Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017 , 35, 717-726	4.4	6
12	Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017 , 35, 97-109	4.4	7
11	Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016 , 34, 245-57	4.4	14

10	A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. <i>Health Technology Assessment</i> , 2016 , 20, 1-414	4.4	58
9	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. <i>Health Technology Assessment</i> , 2016 , 20, 1-326	4.4	32
8	A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. <i>Pharmacoeconomics</i> , 2016 , 34, 1023-38	4.4	17
7	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. <i>Health Technology Assessment</i> , 2015 , 19, v-vi, 1-102	4.4	26
6	Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins. <i>British Journal of Surgery</i> , 2014 , 101, 1040-52	5.3	49
5	Assurance calculations for planning clinical trials with time-to-event outcomes. <i>Statistics in Medicine</i> , 2014 , 33, 31-45	2.3	14
4	Prehospital noninvasive ventilation for acute respiratory failure: systematic review, network meta-analysis, and individual patient data meta-analysis. <i>Academic Emergency Medicine</i> , 2014 , 21, 960-70 ^{3,4}		36
3	Systematic Review and Meta-Analysis of the Association Between Transfusion Independence (TI) and Overall Survival (OS) in Patients (pts) with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014 , 124, 1934 ^{2,7} 1934 ¹		
2	What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2014 , 18, 1-120	4.4	42
1	Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal. <i>Pharmacoeconomics</i> , 2013 , 31, 981-90	4.4	8